Unexpected recovery of ovarian function many years after bone marrow transplantation

The Journal of Pediatrics
Samar N Rahhal, Erica A Eugster

Abstract

Premature ovarian failure as a consequence of childhood cancer treatment is considered permanent when present long after the initial insult. We report spontaneous recovery of ovarian function occurring 8 years after bone marrow transplantation in a girl with history of leukemia and growth hormone deficiency. Clinical management challenges are discussed.

References

Feb 1, 1997·The Journal of Pediatrics·K SarafoglouC Sklar
Mar 7, 1998·Bone Marrow Transplantation·E ThibaudR Brauner
Apr 29, 1999·Medical and Pediatric Oncology·V PapadakisC Sklar
Mar 24, 2005·Journal of the National Cancer Institute. Monographs·Charles Sklar
Feb 24, 2006·The Journal of Clinical Endocrinology and Metabolism·Wassim ChemaitillyCharles A Sklar

❮ Previous
Next ❯

Citations

Oct 11, 2011·Pediatric Clinics of North America·Vidhya Viswanathan, Erica A Eugster
Aug 3, 2010·Journal de gynécologie, obstétrique et biologie de la reproduction·C BasilleR Fanchin
Dec 1, 2009·Endocrinology and Metabolism Clinics of North America·Vidhya Viswanathan, Erica A Eugster
Jul 29, 2008·Current Opinion in Obstetrics & Gynecology·Kutluk Oktay, Murat Sönmezer
Oct 31, 2008·Current Opinion in Endocrinology, Diabetes, and Obesity·Murat Sönmezer, Kutluk Oktay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.